Innovent Biologics, Inc. (HKG: 1801)

Innovent Biologics Revenue

Innovent Biologics had revenue of 3.95B CNY in the half year ending June 30, 2024, with 76.47% growth. This brings the company's revenue in the last twelve months to 7.46B, up 48.59% year-over-year. In the year 2023, Innovent Biologics had annual revenue of 6.21B with 36.21% growth.

• Revenue (ttm): 7.46B CNY
• Revenue Growth: +48.59%
• P/S Ratio: 6.21
• Revenue / Employee: 1.53M CNY
• Employees: 4,872
• Market Cap: 50.86B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	6.21B	1.65B	36.21%
Dec 31, 2022	4.56B	286.65M	6.71%
Dec 31, 2021	4.27B	425.91M	11.08%
Dec 31, 2020	3.84B	2.80B	266.94%
Dec 31, 2019	1.05B	1.04B	10,953.34%